GCV Symposium 2017
Skip Content

7 January 2015

Juno completes IPO

Juno Therapeutics completes initial public offering, with stocks soaring.

Author: Gregg Bayes-Brown, editor

Immunotherapy firm Juno Therapeutics has completed its IPO, trading on the Nasdaq under the ticker symbol “JUNO” since 22 December.

Juno offered 12.7 million shares of common stock at $24 per share. By 29 December, the share price had more than doubled to $54 per share. After a sell off at the start of the year bringing the price down to $46 per share, the price has subsequently recovered to $51.66 per share at time of writing.

The company, launched in December 2013, raised $310m over two rounds in 12 months. Backers include Bezos Expeditions, Arch Venture Partners, Venrock, and Alaska Permanent Fund.

At the core of Juno’s intellectual property is an oncology treatment which reprograms white blood cells to be able to recognise, target, and eradicate tumours. Early trials into the technology at Juno and its immunotherapy peers have shown a great deal of promise, with a high rate of complete remissions.

Copyright Mawsonia Limited 2010. Please don´t cut articles from www.globaluniversityventuring.com or the PDF and redistribute by email or post to the web without written permission.

  • Linkedin
  • Mail
  • Rssfeed
Trial Subscribe now

Latest Magazine

GCV Symposium 2017

Editor’s picks

Most popular


23 April 2017

UniVenture Visions 2017 Symposium – Hong Kong

The Coller Institute of Venture and the AUTM Asia 2017 Conference have announced UniVenture Visions, an exclusive symposium that shall trigger the thinking and discussion necessary to evolve research universities…

23 May 2017

GCV Symposium 2017 - London

Join 400+ business leaders from the corporate venturing and wider high growth business ecosystem for the two-day 2017 GCV Symposium.